ERBB2 and breast cancer: Finally, a recent preclinical study showed a significant dysregulation of four miRNAs (miR-23b-3p, miR-195-5p, miR-656-5p, miR-340-5p) in HER2-positive BC-resistant BT-474 cells, suggesting potential involvement of these miRNAs in trastuzumab resistance mechanisms [91].